Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 137

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 137
---

compositions comprising MEAI and N-acylethanolamines, for example, Palmitoylethanolamide, or PEA, and methods for their use in a variety
of indications amenable to treatment with MEAI.

MEAI for the Treatment of Cocaine Addiction patent
family was filed jointly with BIRAD on May 31, 2023, and is part of our cooperation agreement with SciSparc. The invention disclosed therein
is directed to the methods for treating cocaine addiction by administering a therapeutically effective amount of MEAI and the methods
of treatment comprise administering MEAI in combination with N-acylethanolamines, for example, PEA.

MEAI for the Treatment of Metabolic Syndrome patent
family was filed jointly with Yissum, on September 20, 2023. The invention disclosed therein is directed to the methods for treating metabolic
syndrome by administering a therapeutically effective amount of MEAI and methods comprising administering MEAI in combination with N-acylethanolamines,
for example, PEA.

Compositions comprising 3MMC and n-acylethanolamines
and methods for treating dyskinesias such as tardive dyskinesia is a patent family filed on July 27, 2023, as part of our cooperation
agreement with SciSparc. The invention disclosed therein is directed to compositions and methods for potentiating therapeutic effects
and/or reducing side-effects of 3MMC. The present invention provides pharmaceutical compositions comprising 3MMC and N-acylethanolamines,
for example, Palmitoylethanolamide, or PEA, and methods for their use in treating dyskinesias such as tardive dyskinesia.

Compositions comprising 3,4-METHYLENEDIOXYMETHAMPHETAMINE
and n-acylethanolamines and uses thereof is a patent family filed on February 15, 2023, as part of our cooperation agreement with SciSparc.
The invention disclosed therein is directed to the compositions and methods for potentiating therapeutic effects and/or reducing side-effects
of 3,4-METHYLENEDIOXYMETHAMPHETAMINE. The present disclosure encompasses compositions and methods for potentiating therapeutic effects
and/or reducing side-effects of 3,4-methylenedioxymethamphetamine (MDMA). The disclosure provides pharmaceutical compositions and combinations
comprising MDMA and N-acylethanolamines